These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7399551)

  • 1. Immunotherapy of advanced carcinoma maxilla with immunosensitised porcine mesentric lymph node cells with immunospecific xenogenic lymphnode cell transfer factor.
    Jamkar AV
    Indian J Cancer; 1980 Mar; 17(1):25-30. PubMed ID: 7399551
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunotherapy of malignant tumors in man].
    Govalle VI
    Vopr Onkol; 1976; 22(3):99-109. PubMed ID: 779262
    [No Abstract]   [Full Text] [Related]  

  • 3. [Proceedings: Immunomanipulation- -immunotherapy].
    Grob PJ; Hitzig W
    Med Klin; 1975 Jun; 70(23):1010. PubMed ID: 1107776
    [No Abstract]   [Full Text] [Related]  

  • 4. [Specific active immunotherapy of cancer].
    Valladares Y
    An R Acad Nac Med (Madr); 1982; 99(1):109-46. PubMed ID: 6181704
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cell immunity responses in patients with widespread neoplasias following administration of transfer factor (author's transl)].
    Simó-Camps E; Vich JM; García Calderón PA; Bofill D; Grau A; Anguiz A; Forcadell I
    Med Clin (Barc); 1980 May; 74(10):403-7. PubMed ID: 6968012
    [No Abstract]   [Full Text] [Related]  

  • 6. [Transfer factor immunotherapy of oncological patients].
    Berezhnaia NM; Slinchak SM; Petrovskaia IA; Bezverkhiĭ VD; Kotova SA
    Vopr Onkol; 1981; 27(2):89-91. PubMed ID: 7210602
    [No Abstract]   [Full Text] [Related]  

  • 7. Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.
    Pineda B; Estrada-Parra S; Pedraza-Medina B; Rodriguez-Ropon A; Pérez R; Arrieta O
    J Exp Clin Cancer Res; 2005 Dec; 24(4):575-83. PubMed ID: 16471320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive immunotherapy of cancer in animals and man.
    Rosenberg SA; Terry WD
    Adv Cancer Res; 1977; 25():323-88. PubMed ID: 326003
    [No Abstract]   [Full Text] [Related]  

  • 9. [Immunotherapy of advanced pulmonary tuberculosis with specific transference factor].
    Estrada Parra S; Velasco Castrejón O; Rébora F; Díaz ML; Padierna J
    Salud Publica Mex; 1983; 25(6):579-90. PubMed ID: 6665598
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intratumoral injection of immature dendritic cells (DC) for cancer patients].
    Takeda T; Makita K; Okita K; Haba A; Xianhui D
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1574-5. PubMed ID: 16315873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
    J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.
    Meneses A; Verastegui E; Barrera JL; de la Garza J; Hadden JW
    Int Immunopharmacol; 2003 Aug; 3(8):1083-91. PubMed ID: 12860165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of xenogenic dermal matrix implantation in immunocompetent rats.
    DeSagun EZ; Botts JL; Srivastava A; Hanumadass M; Walter RJ
    J Surg Res; 2001 Mar; 96(1):96-106. PubMed ID: 11181002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of cancer with "immune" RNA: current status.
    Pilch YH; deKernion JB
    Semin Oncol; 1974 Dec; 1(4):389-95. PubMed ID: 4620442
    [No Abstract]   [Full Text] [Related]  

  • 15. [The experimental treatment of laryngeal cancer using local draining lymph node lymphocytes].
    Wu Y; Guo M
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(1):26-8. PubMed ID: 9275399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-rosette forming count determination and transfer factor treatment in herpetic simplex keratitis.
    Xie LX; Kang FY; Du YX
    Chin Med J (Engl); 1983 Nov; 96(11):860-4. PubMed ID: 6428821
    [No Abstract]   [Full Text] [Related]  

  • 17. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Selection of therapy in precanceroses and malignomas in the maxillofacial region: surgery, radiotherapy, chemotherapy immunotherapy?].
    Sailer HF
    SSO Schweiz Monatsschr Zahnheilkd; 1977 Dec; 87(12):1181-96. PubMed ID: 74093
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: effects on chemokine production.
    Triozzi PL; Aldrich W; Bresler HS; Para MF; Flancbaum LJ
    J Infect Dis; 1999 Jan; 179(1):245-8. PubMed ID: 9841848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
    Cesano A; Visonneau S; Santoli D
    Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.